(Q36164799)

12 August 2017

1 reference

title

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate (English)

1 reference

12 August 2017

8

1 reference

12 August 2017

David L Kendler

6

0 references

Roberto Civitelli

object named as

Roberto Civitelli

10

0 references

Cyrus Cooper

object named as

Cyrus Cooper

3

0 references

Jean-Yves Reginster

1

object named as

Jean-Yves Reginster

1 reference

12 August 2017

2

Dieter Felsenberg

1 reference

12 August 2017

4

Jacob A Stakkestad

1 reference

12 August 2017

9

Michael A Bolognese

1 reference

12 August 2017

13

Robert R Recker

1 reference

12 August 2017

7

Silvano Adami

1 reference

12 August 2017

Paul D Miller

5

1 reference

12 August 2017

Etienne Dumont

11

1 reference

12 August 2017

Bernard Bonvoisin

12

1 reference

12 August 2017

Pierre D Delmas

14

1 reference

12 August 2017

language of work or name

English

0 references

publication date

14 June 2005

1 reference

Osteoporosis International

12 August 2017

1 reference

12 August 2017

17

1 reference

12 August 2017

2

1 reference

12 August 2017

159-166

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-005-1957-6

12 August 2017

0 references

cites work

Epidemiology of hip fractures

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-005-1957-6

Weekly administration of alendronate: rationale and plan for clinical assessment

21 January 2018

1 reference

12 December 2020

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

12 December 2020

Intermittent cyclic tiludronate in the treatment of osteoporosis

1 reference

12 December 2020

Compliance with pharmacologic therapy for osteoporosis

1 reference

12 December 2020

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

12 December 2020

Early discontinuation of treatment for osteoporosis

1 reference

12 December 2020

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

1 reference

12 December 2020

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension

1 reference

12 December 2020

Surrogates for fracture endpoints in clinical trials

1 reference

12 December 2020

A medication use evaluation of alendronate: compliance with administration guidelines.

1 reference

12 December 2020

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat

1 reference

12 December 2020

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

12 December 2020

Hip fractures in the elderly: a world-wide projection

1 reference

12 December 2020

The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.

1 reference

12 December 2020

A systematic review of the associations between dose regimens and medication compliance

1 reference

12 December 2020

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

1 reference

12 December 2020

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

Consequences of a hip fracture: a prospective study over 1 year

1 reference

12 December 2020

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

12 December 2020

Population-based study of survival after osteoporotic fractures

1 reference

12 December 2020

The socioeconomic burden of fractures: today and in the 21st century

1 reference

12 December 2020

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

1 reference

12 December 2020

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

1 reference

12 December 2020

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

1 reference

12 December 2020

Age-related osteoporosis.

1 reference

12 December 2020

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

1 reference

12 December 2020

Study designs in osteoporosis

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Patients with osteoporosis prefer once weekly to once daily dosing with alendronate

1 reference

12 December 2020

Lineage commitment and maturation of epithelial cells in the gut.

1 reference

12 December 2020

Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats

1 reference

12 December 2020

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review

1 reference

12 December 2020

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Tolerability and compliance with risedronate in clinical practice

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

1 reference

12 December 2020

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies

1 reference

12 December 2020

Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S00198-005-1957-6

Identifiers

DOI

1 reference

12 August 2017

1 reference